Comment on If I Were a Valeant Pharmaceuticals Shareholder, This Would Infuriate Me

If I Were a Valeant Pharmaceuticals Shareholder, This Would Infuriate Me

Image source: Getty Images.Drugmaker Valeant Pharmaceuticals (NYSE: VRX) has had a really rough go of things over the past year. Since peaking at approximately $264 a share last summer, shares of the once nearly megacap company have fallen back into mid-cap status.At the heart of Valeant's issues are its pricing practices under the leadership of now-former CEO J.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News